ZLAB News and Press, Zai Lab Limited From 05/18/23

2023-05-18 08:50:29 ET China's National Medical Products Administration (NMPA) granted priority review to Zai Lab's ( NASDAQ: ZLAB ) repotrectinib to treat adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer (NSCLC). A priority...

SHANGHAI, China and CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted priority review to repotrectinib for the treatm...

2023-05-10 14:08:07 ET Zai Lab Limited. (ZLAB) Q1 2023 Earnings Conference Call May 10, 2023, 08:00 AM ET Company Participants Billy Cho - Chief Financial Officer Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - Chief Operating Officer...

2023-05-09 16:23:21 ET Zai Lab press release ( NASDAQ: ZLAB ): Q1 GAAP EPS of -$0.05 beats by $0.88 . Revenue of $62.79M (+34.4% Y/Y) misses by $2.68M . For further details see: Zai Lab GAAP EPS of -$0.05 beats by $0.88, revenue of $62.79M misses by $2.68M

Total product revenue of $62.8 million for the first quarter of 2023, representing a 36% increase y-o-y; ZEJULA® achieved 44% y-o-y growth Expansion of Zai Lab’s lung cancer franchise and global oncology pipeline with a next generation antibody-drug conjugate (ADC) program...

2023-04-27 09:17:33 ET Zai Lab ( NASDAQ: ZLAB ) signed a licensing agreement with MediLink Therapeutics for a next generation anti-body-drug conjugate (ADC) to treat cancer cancer. Zai said via the collaboration, it has expanded its lung cancer franchise and global oncology pi...

SHANGHAI, China and CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics (MediLink). MediLink is an innovative drug development company focusing ...

SHANGHAI and CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American Society of ...

SHANGHAI, China and CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the first quarter of 2023 and recent corporate updates after the closing of the U.S. equity markets on May 9, 2023. The Com...

SHANGHAI and CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data including a translational and biomarker data analysis from its internal oncology discovery program ZL-1211 at the upcoming 2023 American Association for Cancer Resear...